Close
Achema middle east
swop processing & packaging

Pharnext, UHI to Evaluate Repurposed Drugs Against COVID-19

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

Amcor to showcase responsible and patient-centric packaging innovations at CPHI Frankfurt 2025

User-friendly solutions designed to enhance convenience, performance and patient...

Kadans Science Partner secures one of the most significant deals in Glasgow of H1 2025

Chemify scales up operations at Health Innovation Hub Digital...

CPHI 2025: BENEO to present galenIQ™ as the granulation binder of choice

At this year’s CPHI Europe in Frankfurt (28–30 October),...

Pharnext, a clinical-stage biopharma company developing drug combinations based on big genomic data and artificial intelligence (AI), and the University Hospital Institute Méditerranée Infection, devoted to infectious and tropical diseases in France, have partnered to research potential drug candidates to fight COVID-19 virus.

The joint activities will focus on rapidly testing in vitro a number of already approved drugs that were previously identified by Pharnext as potential candidates for fighting COVID-19 using its PLEOTHERAPY AI platform. The testing will also include several high priority drug combination candidates against COVID-19, also using the PLEOTHERAPY AI platform. The testing will be performed by the UHI Méditerranée Infection in preclinical studies.

“We anticipate that with such an efficient and highly qualified team, important in vitro results will be forthcoming” said Daniel Cohen, M.D., Ph.D., Founder and President of the Scientific Advisory Board of Pharnext.

“We are all engaged in the same medical fight to treat COVID-19 patients as fast as possible to slow down the epidemic and prevent, treat severe forms of the disease” said Didier Raoult, M.D., Ph.D., Founder and Head of the UHI Méditerranée Infection.

Latest stories

Related stories

Amcor to showcase responsible and patient-centric packaging innovations at CPHI Frankfurt 2025

User-friendly solutions designed to enhance convenience, performance and patient...

Kadans Science Partner secures one of the most significant deals in Glasgow of H1 2025

Chemify scales up operations at Health Innovation Hub Digital...

CPHI 2025: BENEO to present galenIQ™ as the granulation binder of choice

At this year’s CPHI Europe in Frankfurt (28–30 October),...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »